Anybuddy
Venture Round in 2025
Anybuddy is a French-based sports booking platform specializing in racket sports. It facilitates match arrangements for football or tennis, offering users access to various sports facilities and payment options through its user-friendly application.
Founded in 2019, Syroco is an innovation lab based in Marseille, France. It operates a scientific laboratory focused on improving energy and transportation industries' systemic efficiency through 'moonshot challenges'. The company designs and develops cutting-edge technologies to achieve extreme challenges, such as creating a speed craft for sailing records.
Aenitis Technologies
Venture Round in 2024
A French startup created by CNRS researchers at the Physics and Mechanics of Heterogeneous Media (PMMH) Laboratory in Paris, Aenitis Technologies develops bioprocessing medical devices that use acoustophoresis to separate, manipulate and filter biological elements, with a focus on cell therapy manufacturing such as cell sorting, washing and isolation for cell therapy units and blood banks. The company aims to provide acoustic preparation solutions to streamline cell therapies and advance public health, pursuing leadership in acoustophoresis-based separation.
MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.
Nexess
Venture Round in 2024
Founded in 2006, Nexess specializes in developing and selling advanced security management solutions for nuclear and high-risk industrial plants. Its product portfolio includes RFID tags, smart cameras, antenna systems, and software platforms designed to enhance traceability, productivity, and security. Headquartered in Mougins, France, with an additional office in Paris, the company serves clients aiming to improve their operational efficiency and safety.
Eligo Bioscience
Series B in 2023
Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.
Mediarithmics
Venture Round in 2023
Founded in 2011, Mediarithmics operates a cloud-based data marketing platform headquartered in Fontenay-sous-Bois, France. The company enables brands to manage retargeting campaigns across multiple devices and allows agencies to handle clients' RTB and email campaigns through a single tool.
Domain Therapeutics
Series A in 2022
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.
HARDLOOP
Venture Round in 2022
Founded in Paris, France in 2014, HARDLOOP is an online retailer specializing in sports products. It offers a wide range of items including shoes, gloves, bottles, and other accessories for various adventure sports such as hiking, running, skiing, climbing, and swimming.
SportEasy
Series A in 2021
SportEasy is a web and mobile platform that helps amateur sports teams manage their activities. It enables coaches and managers to organize games and practices, coordinate communication with players, and track team statistics and insights. The application includes social features that let players share updates and engage with teammates, while reducing administrative tasks for mentors, coaches, volunteers, and players so they can focus more on the field. The service is available on web and mobile devices and supports multiple languages. Launched in France in 2011, SportEasy targets grassroots sports environments through an integrated scheduling, messaging, and data-capture solution.
Expensya is a Paris-based provider of expense management software that automates professional expense reports across web and mobile platforms. The Expensya platform handles expense capture and processing, approval workflows, data export, accountant integration, archiving, email processing, mileage tracking, cost accounting, and scanning, with analytics. It runs on cloud and uses AI, machine learning, big data, and business intelligence to streamline operations. The solution is available in multiple languages and adapts to local accounting rules in roughly fifty countries. The company was founded in 2014 and is headquartered in Paris, France.
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
Scipio Bioscience
Series A in 2020
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
MaaT Pharma
Series B in 2020
MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.
HARDLOOP
Venture Round in 2020
Founded in Paris, France in 2014, HARDLOOP is an online retailer specializing in sports products. It offers a wide range of items including shoes, gloves, bottles, and other accessories for various adventure sports such as hiking, running, skiing, climbing, and swimming.
TIBOT Technologies
Seed Round in 2019
Founded in 2016, TIBOT Technologies designs and develops robots to enhance poultry farming. Its flagship products include Spoutnic, an assistant robot, and Spoutnic NAV, a robot for scrape, drink, and feed tasks. The company aims to improve animal welfare and profitability while easing the workload of farmers.
JobTeaser
Series C in 2019
JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.
LNC Therapeutics
Venture Round in 2019
LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.
Domain Therapeutics
Venture Round in 2019
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.
Expensya
Venture Round in 2018
Expensya is a Paris-based provider of expense management software that automates professional expense reports across web and mobile platforms. The Expensya platform handles expense capture and processing, approval workflows, data export, accountant integration, archiving, email processing, mileage tracking, cost accounting, and scanning, with analytics. It runs on cloud and uses AI, machine learning, big data, and business intelligence to streamline operations. The solution is available in multiple languages and adapts to local accounting rules in roughly fifty countries. The company was founded in 2014 and is headquartered in Paris, France.
Presto Engineering
Venture Round in 2018
Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.
Launchmetrics
Venture Round in 2018
Launchmetrics is a marketing and analytics platform that specializes in serving the fashion, luxury, and beauty industries. Founded in 2006 and headquartered in New York, with additional operations in Paris, the company offers a suite of products designed to enhance brand performance and streamline marketing processes. Its offerings include Samples, Events, Contacts, Discover, and Influencers by Launchmetrics, which collectively assist brands in planning product launches and improving media performance. The company has established itself as a trusted technology provider, working with over 1,000 clients, including prominent names like Dior, Fendi, and NET-A-PORTER, as well as partners such as the British Fashion Council and Google. With a presence in eight markets and support in five languages, Launchmetrics aims to empower brands to create impactful and measurable consumer experiences, adapting to the rapidly changing digital landscape. The company was originally known as Fashion GPS, Inc. before rebranding in January 2016.
MDoloris Medical Systems
Private Equity Round in 2018
MDoloris Medical Systems SAS is a French company founded in 2010, specializing in the development and manufacture of medical devices aimed at monitoring and assessing patient pain. The company is known for its Analgesia Nociception Index (ANI) monitors, which provide a direct measurement of autonomic nervous system activity, and are particularly useful for non-communicating patients. These devices are employed in various settings, including general anesthesia, post-surgical care, intensive care units, obstetrics, and neonatal care. Additionally, MDoloris offers after-sales services to support its products. By enabling clinicians to better understand and manage patient pain, the company enhances the effectiveness of analgesic treatment and improves patient outcomes across multiple healthcare environments.
Enterome
Debt Financing in 2018
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
Scipio Bioscience
Seed Round in 2017
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
LNC Therapeutics
Series C in 2017
LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.
Eligo Bioscience
Series A in 2017
Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.
Intento Design
Series B in 2017
Intento Design SA, founded in 2015 and based in Paris, France, specializes in developing software that enhances the efficiency of analog and mixed-signal integrated circuit development. The company's flagship product, ID-Xplore, automates the analog design process from hand analysis to simulation, significantly reducing the time required for circuit sizing. Intento Design also provides services such as methodology adoption, design collaboration, and technology migration. Their solutions are tailored for designers in various markets, including consumer electronics, Internet of Things, big data, military, and medical sectors. The company's innovative approach originated from research conducted at Laboratoire d’Informatique de Paris 6, resulting in a robust portfolio of intellectual property focused on accelerating the design cycle for complex systems-on-chips (SoCs).
TargEDys is a biotechnology company based in Rouen, France, established in 2011. The company focuses on developing innovative mechanisms that utilize hormone mimetic proteins associated with the gut microbiota to address eating disorders, including hyperphagia and anorexia. TargEDys' approach aims to regulate appetite and metabolic functions by leveraging naturally occurring bacterial proteins found in the gut. This technology is designed to help overweight individuals manage their eating behavior and restore appetite in populations such as the elderly or those suffering from cachexia or anorexia. Through its research and development efforts, TargEDys seeks to provide effective solutions for appetite modulation and the treatment of related metabolic diseases.
Business Table
Venture Round in 2017
Business Table is the leader in corporate dining and corporate events, with more than 30,000 service providers, including 15,000 restaurants, 1,500 caterers and 14,000 hotels and locations across France.
This innovative solution launched in 2012 allows companies, from large groups to SMEs, to streamline the management of meal costs through a simple, innovative and efficient booking, ordering and invoicing tool. To expand its service offering, Business Table has partnered with American Express, Concur, Edenred and AirPlus
Botfuel
Seed Round in 2017
Botfuel, established in 2016 and headquartered in Paris, France, specializes in a web-based platform and SDK for creating and deploying chatbots. It empowers individuals and businesses to engage with customers on popular messaging channels, providing automated, personalized support and enhancing brand engagement. The platform leverages AI to develop modular, scalable chatbots, aiming to improve customer support and drive sales.
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
TargEDys is a biotechnology company based in Rouen, France, established in 2011. The company focuses on developing innovative mechanisms that utilize hormone mimetic proteins associated with the gut microbiota to address eating disorders, including hyperphagia and anorexia. TargEDys' approach aims to regulate appetite and metabolic functions by leveraging naturally occurring bacterial proteins found in the gut. This technology is designed to help overweight individuals manage their eating behavior and restore appetite in populations such as the elderly or those suffering from cachexia or anorexia. Through its research and development efforts, TargEDys seeks to provide effective solutions for appetite modulation and the treatment of related metabolic diseases.
MaaT Pharma
Series A in 2016
MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.
MilliDrop
Seed Round in 2016
MilliDrop Instruments SAS is a Paris-based company that specializes in the design and development of advanced cell culture machines utilizing millifluidics technology for bacteriological research and diagnostics. Established in 2015, MilliDrop focuses on creating innovative in vitro diagnostics instruments, such as the MilliDrop DIV, which facilitate the identification of infectious agents and the determination of appropriate antibiotic dosages. These instruments allow for the incubation, analysis, and manipulation of microscopic samples ranging from approximately 100 nanoliters to a few picoliters in volume. By enabling microbiologists to simultaneously study various cultures, monitor phenotypic diversity, and conduct serial dilutions, MilliDrop enhances the efficiency and accuracy of antimicrobial susceptibility testing across a range of microorganisms, including bacteria, fungi, and yeasts.
HorseCom
Seed Round in 2016
HorseCom SAS is a French company based in Caen, established in 2015, that specializes in developing innovative Bluetooth audio headset technology for horses and riders. The company aims to enhance the well-being, performance, and connection between horses and their riders through its patented audio products. HorseCom's offerings include a wearable device designed specifically for equine ears, which diffuses music to both horse and rider, promoting synchronization during training and enhancing the overall riding experience. This technology not only improves the horse's well-being but also aids in recovery and reduces stress in challenging situations. Additionally, the company provides a mobile application to complement its audio kits, which consist of Bluetooth earpieces for riders, a cap with a Bluetooth receiver, and earphones for horses, all aimed at building effective training programs in equestrian sports.
Intento Design
Venture Round in 2015
Intento Design SA, founded in 2015 and based in Paris, France, specializes in developing software that enhances the efficiency of analog and mixed-signal integrated circuit development. The company's flagship product, ID-Xplore, automates the analog design process from hand analysis to simulation, significantly reducing the time required for circuit sizing. Intento Design also provides services such as methodology adoption, design collaboration, and technology migration. Their solutions are tailored for designers in various markets, including consumer electronics, Internet of Things, big data, military, and medical sectors. The company's innovative approach originated from research conducted at Laboratoire d’Informatique de Paris 6, resulting in a robust portfolio of intellectual property focused on accelerating the design cycle for complex systems-on-chips (SoCs).
MaaT Pharma
Seed Round in 2015
MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.
Mailjet is a comprehensive email service provider founded in France in 2010. It specializes in delivering marketing and transactional emails, serving over 26,000 clients in 156 countries and facilitating the transmission of nearly 1 billion emails each month. The company offers a real-time cloud emailing platform that enables clients to send, track, and optimize their email communications effectively. Mailjet's proprietary technology includes advanced analytics tools and intelligent APIs, along with features like A/B testing and Campaign Comparison, which enhance email performance. Additionally, the company provides consulting services to ensure optimal deliverability, supported by a multilingual customer service team available around the clock.
Eligo Bioscience
Seed Round in 2015
Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.
Augure is a software company founded in 2002 in Paris, specializing in influencer marketing and public relations solutions. The company offers a platform that assists brands and agencies in managing their communication strategies by bridging the gap between traditional PR and influencer marketing. With over 1,000 clients utilizing the platform daily, Augure enables communication, PR, and public affairs teams to engage with relevant influencers, streamline campaign management, and enhance their media presence on social networks. In addition to its software, Augure provides consulting services through its data services team, helping clients interpret and leverage data to optimize their influencer marketing strategies. The company operates primarily in Europe and Latin America, serving a diverse range of clients, including prominent organizations in the corporate sector.
Aenitis Technologies
Seed Round in 2015
A French startup created by CNRS researchers at the Physics and Mechanics of Heterogeneous Media (PMMH) Laboratory in Paris, Aenitis Technologies develops bioprocessing medical devices that use acoustophoresis to separate, manipulate and filter biological elements, with a focus on cell therapy manufacturing such as cell sorting, washing and isolation for cell therapy units and blood banks. The company aims to provide acoustic preparation solutions to streamline cell therapies and advance public health, pursuing leadership in acoustophoresis-based separation.
Open Ocean
Seed Round in 2015
Open Ocean SAS is a French company, established in 2011 and operating out of Brest and Paris, that specializes in developing SaaS-based decision-making platforms for offshore infrastructure and marine operations. The company offers a range of innovative solutions, including the Metocean Analytics tool, which analyzes atmospheric and oceanic conditions, and provides comprehensive reports on tidal energy markets in France. Additionally, Open Ocean produces a spectral wave database to support the development of marine renewable energy in Scotland. Their services include site data analysis, resource and energy assessment, environmental impact assessments, and adherence to greenhouse gas protocols for wave and tidal energy projects. Open Ocean's highly qualified team of oceanographers, trained at leading research institutions, focuses on high-resolution modeling, statistical analysis, and data mining, catering to farm developers, operators, and public agencies in the renewable marine energy sector. As of September 2019, Open Ocean operates as a subsidiary of Artelia SAS.
JobTeaser
Series A in 2015
JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.
MaaT Pharma
Seed Round in 2015
MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
Webinterpret
Series A in 2014
Webinterpret, established in 2007, focuses on making international e-commerce accessible to sellers worldwide. With offices in France, Poland, China, and the USA, the company employs approximately 210 skilled e-commerce specialists who possess in-depth local market knowledge. Webinterpret operates a global marketplace platform designed to help online merchants expand their reach internationally. The platform offers a range of services, including adjustments to shipping costs, currency conversion, product categorization, accurate translations, and international stock management. These services enable online retailers and marketplace sellers to effectively grow their businesses on a global scale and enhance their online sales.
Streamdata.io
Series B in 2013
Founded in 2008, Streamdata.io specializes in API management software designed to streamline data using event-driven infrastructure. Its core product is a machine-learning-based cache proxy that reduces bandwidth consumption for web, mobile, and IoT platforms. The company also offers services to help businesses progress through their API lifecycle and discover digital assets.
Global Bioenergies
Post in 2013
Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.
Advanced Accelerator Applications
Private Equity Round in 2013
Advanced Accelerator Applications develops and commercializes molecular nuclear medicine products for diagnosis and therapy. Its portfolio includes radiopharmaceuticals like oxodotreotides, dotatate injections, and edotreotide solutions, targeting oncology, cardiology, and neurology. The company also offers theragnostic platforms for precision imaging and targeted therapies.
Nexess
Venture Round in 2013
Founded in 2006, Nexess specializes in developing and selling advanced security management solutions for nuclear and high-risk industrial plants. Its product portfolio includes RFID tags, smart cameras, antenna systems, and software platforms designed to enhance traceability, productivity, and security. Headquartered in Mougins, France, with an additional office in Paris, the company serves clients aiming to improve their operational efficiency and safety.
Recommerce Group
Venture Round in 2013
Recommerce Group specializes in the trade-in, refurbishment, and remarketing of second-hand smartphones across Europe. Founded in 2009 and headquartered in Paris, France, the company employs advanced proprietary technologies to give a second life to mobile devices, offering a wide array of premium quality products under its own brand. Recommerce Group provides comprehensive solutions that include buyback services, real-time market pricing, and leasing programs, facilitating affordable access to refurbished electronics. The company serves a diverse clientele, including mobile network operators, distributors, e-tailers, and manufacturers, through both online and physical distribution channels in France, Switzerland, Spain, and beyond. Additionally, Recommerce Group offers marketing and logistical support, as well as customer services, ensuring a seamless experience for its partners and customers alike.
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.
Biophytis
Series B in 2012
Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.
Web Geo Services
Series A in 2012
Web Geo Services SAS, founded in 2009 and headquartered in Montpellier, France, specializes in online mapping and geolocation technology tailored for various sectors, including retail, e-commerce, travel, banking, and automotive. The company empowers businesses to utilize Google Maps effectively, enhancing customer engagement and driving conversions. As a strategic partner of Google Cloud and recognized as the leading Google Maps partner in Europe, Web Geo Services supports over 400 large enterprises in rapidly deploying digital systems that optimize online checkout and customer journeys. Their flagship platform, Woosmap, offers developers robust Location Intelligence features for mobile apps and websites. Furthermore, Web Geo Services develops cloud-based geolocation solutions that facilitate community engagement and streamline operational processes for businesses, ultimately helping clients boost their revenue through innovative location-based services.
Domain Therapeutics
Venture Round in 2012
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.
ProTip SA is a privately held medical device company dedicated to the development of innovative solutions for patients suffering from larynx malfunctions. Its priority focus is to develop a permanent implant for laryngectomized patients. ProTip, based in Strasbourg (Eastern France), was founded in 2004 and has since benefited from strong support from the Alsace region and Oseo, the French public agency for innovation. The company has won several prestigious awards in France. It has established partnerships with a number of academic institutions. The international expansion of the company has recently accelerated due to the ISO certification and CE mark achievement on essential product lines.
LNC Therapeutics
Series B in 2012
LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
Streamdata.io
Series A in 2011
Founded in 2008, Streamdata.io specializes in API management software designed to streamline data using event-driven infrastructure. Its core product is a machine-learning-based cache proxy that reduces bandwidth consumption for web, mobile, and IoT platforms. The company also offers services to help businesses progress through their API lifecycle and discover digital assets.
Impeto Medical
Series B in 2011
Impeto Medical SAS is a privately owned medical device company established in June 2005, with its headquarters located in Paris, France, and additional subsidiaries in China and San Diego, California. The company specializes in the manufacture and marketing of non-invasive diagnostic devices that assess eccrine sweat gland activity. Its product lineup includes SUDOSCAN+, which is used for detecting and monitoring peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardio metabolic risks; and SUDOSCAN, a device that evaluates galvanic skin response to assess sympathetic nervous system behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical's innovative technology enables healthcare professionals to screen large patient populations effectively, facilitating early detection of metabolic disorders and related complications. The company distributes its products through a network of distributors.
Talentsoft
Venture Round in 2011
Talentsoft, established in 2007, is a leading French software company specializing in cloud-based Talent Management solutions. It offers a comprehensive suite of services, including recruitment, onboarding, performance management, and learning management, all integrated on a single platform. Talentsoft has achieved rapid growth and international success by forming strategic partnerships, maintaining high-caliber teams, and providing an attractive technology solution. With numerous awards and financial backing, the company has expanded its global presence to every continent, serving clients through its network of subsidiaries and affiliates.
Enterome
Seed Round in 2011
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.
Arlettie
Venture Round in 2010
Founded in Paris in 1993, Arlettie operates as an online retailer specializing in fashion apparel and accessories. It facilitates private sales events for luxury brands, acting as an intermediary between these brands and customers.
Efficity SAS is an online real estate agency located in Paris, France, established in 2007. The company specializes in providing a range of online real estate services, including the buying and selling of properties, property management, and property valuation. Efficity leverages digital platforms to facilitate real estate transactions, enabling clients to navigate the property market efficiently.
Quescom
Venture Round in 2010
QuesCom S.A. is a company based in Sophia Antipolis, France, specializing in the design and manufacture of internet telecommunication systems. Founded in 1999, QuesCom develops a range of products including business communication management portals, GSM gateways, SIM servers, and mobile call servers. The company also offers VoIP technology and network management software, catering to the needs of enterprises and service providers. Through partnerships with leading telecommunications firms, QuesCom aims to enhance communication solutions and streamline business operations.
Founded in 2006, Implanet designs, manufactures, and sells high-quality orthopedic implants for surgical markets worldwide. Its product portfolio includes spinal fixation systems like Jazz, knee prostheses such as Madison, and other orthopedic devices.
Presto Engineering
Venture Round in 2010
Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.
Talentsoft
Seed Round in 2009
Talentsoft, established in 2007, is a leading French software company specializing in cloud-based Talent Management solutions. It offers a comprehensive suite of services, including recruitment, onboarding, performance management, and learning management, all integrated on a single platform. Talentsoft has achieved rapid growth and international success by forming strategic partnerships, maintaining high-caliber teams, and providing an attractive technology solution. With numerous awards and financial backing, the company has expanded its global presence to every continent, serving clients through its network of subsidiaries and affiliates.
Founded in 2006, Implanet designs, manufactures, and sells high-quality orthopedic implants for surgical markets worldwide. Its product portfolio includes spinal fixation systems like Jazz, knee prostheses such as Madison, and other orthopedic devices.
MLstate
Venture Round in 2009
MLstate is a technology company focused on developing secure communications solutions and industrial web applications. It is well known for its proprietary product, Peps, which is designed to enhance secure digital communication. The company also created Opa, an advanced open-source framework for JavaScript, consisting of a compiler that features a JavaScript-like syntax with numerous improvements, alongside a runtime JavaScript library. MLstate's innovations have garnered recognition in the tech industry, including awards and publications, and the company has been a finalist in various prestigious competitions. MLstate's offerings facilitate email management, document collaboration, and file sharing within organizations, positioning the company as a key player in the development of web exchange platforms.
Webinterpret
Seed Round in 2008
Webinterpret, established in 2007, focuses on making international e-commerce accessible to sellers worldwide. With offices in France, Poland, China, and the USA, the company employs approximately 210 skilled e-commerce specialists who possess in-depth local market knowledge. Webinterpret operates a global marketplace platform designed to help online merchants expand their reach internationally. The platform offers a range of services, including adjustments to shipping costs, currency conversion, product categorization, accurate translations, and international stock management. These services enable online retailers and marketplace sellers to effectively grow their businesses on a global scale and enhance their online sales.
CodaSystem
Venture Round in 2008
CodaSystem is a French start-up that specializes in digital photography technology with legal value. The company provides a real-time monitoring tool that enables users to capture digital photographs using a mobile phone, which can then serve as legal evidence. This innovative software is designed to enhance the reliability and credibility of photographic documentation in various contexts, ensuring that users can easily generate legally admissible images.
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.
VoluBill S.A. is a provider of real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and based in Montbonnot Saint Martin, France, with additional offices in Europe and Asia, the company specializes in solutions for fixed, mobile, and fixed mobile convergent operators. VoluBill's product offerings include CHARGE-IT, which facilitates real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement; and CHARGE-IT Dynamic Charging Platform, which supports various charging models such as pre-pay, post-pay, and now-pay for data services.
Glowria
Venture Round in 2007
Glowria offers online digital video disc (DVD) rental service. Glowria was founded in 2003 is based in Paris, France.
Idylis S.A., established in 2008 and headquartered in Issy-les-Moulineaux, France, specializes in designing, developing, and marketing software solutions tailored for enterprise management. The company's product suite supports a range of applications including audit and accounting, financial management, documentation, e-mailing, scheduling, supply chain management, logistics, and inventory management. Additionally, Idylis offers customer support and consulting services to enhance the effectiveness of its software solutions for clients.
Numara Software France
Series C in 2006
Numara Software France SAS provides information technology (IT) and security management solutions. It offers Precision Desktop Management, an agent-based software designed to overcome IT management complexity; Precision Patch Management, an agent-based software designed to help IT managers to address and optimize the patch deployment process; and Precision Vulnerability Management, a non-intrusive vulnerability scanner. The company also provides services, such as IT asset management, vulnerability lifecycle management, software and configuration management, patch management, applications management, system monitoring, end user support, green IT-power management, OS deployment, and compliance. It serves bank, insurance, finance, distribution, education, government, health, industry, media, services, telecom/Internet, and TRANSPORT industries Antipolis and internationally. Criston SA was formerly known as Metrix Systems SA and changed its name to Criston SA in February 2004. The company was founded in 1997 and is headquartered in Sophia Antipolis, France with additional offices in Japan France, China, and Germany. As of July 13, 2009, Numara Software France SAS operates as a subsidiary of Numara Software, Inc.
DxO, established in 2002 and headquartered in Boulogne, France, specializes in the development and sale of digital image processing products and solutions. Its primary offerings include DxO Optics Pro, a software application for image correction and enhancement, and DxO FilmPack, which gives digital images the style of conventional films. Additionally, DxO licenses its intellectual property of optics and silicon architectures for embedded still and video image processing in camera phones and digital cameras. The company also provides DxO Analyzer, an image quality evaluation solution. DxO serves a diverse range of customers, from consumer electronics manufacturers to photographers and imaging experts, distributing its products through resellers and distributors.
METabolic EXplorer
Series C in 2006
METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.
AssurOne Group
Venture Round in 2006
AssurOne Group is a French company based in Asnières-sur-Seine, specializing in online insurance brokerage services since its founding in 2004. The firm provides a range of insurance products, including life, casualty, property, and automobile insurance, available through both the internet and telephone. AssurOne Group serves a diverse clientele, which includes notable names such as French Generali, AXA, and AG2R La Mondiale. The company operates a platform that facilitates insurance, registration, claims, and contract management services, allowing customers to access negotiated insurance contracts directly from providers without the need for brokers, ensuring competitive pricing. AssurOne Group operates as a subsidiary of Société Centrale Prévoyance SA.
Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.
Sefas Innovation
Venture Round in 2005
Founded in 1991, Sefas Innovation specializes in collaborative document composition and production software. Headquartered in Paris, France, with offices in the UK and US, it supports over 80 staff globally. Its Open Print software suite enables Fortune 500 companies across financial services, banking, insurance, utilities, telecoms, and public sectors to design, compose, and produce personalized B2C documents from multiple data sources.
Idylis S.A., established in 2008 and headquartered in Issy-les-Moulineaux, France, specializes in designing, developing, and marketing software solutions tailored for enterprise management. The company's product suite supports a range of applications including audit and accounting, financial management, documentation, e-mailing, scheduling, supply chain management, logistics, and inventory management. Additionally, Idylis offers customer support and consulting services to enhance the effectiveness of its software solutions for clients.
DSO Interactive
Series B in 2005
DSO Interactive SA designs, develops, and markets software solutions for intermediation of Internet platforms. Its products include auditing and decisional software systems for legal firms. The company also offers information technology and communication consulting services. It was formerly known as Convergence SA and changed its name to DSO Interactive in September 2004. The company was founded in 2001 and is based in Paris, France.
VoluBill S.A. is a provider of real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and based in Montbonnot Saint Martin, France, with additional offices in Europe and Asia, the company specializes in solutions for fixed, mobile, and fixed mobile convergent operators. VoluBill's product offerings include CHARGE-IT, which facilitates real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement; and CHARGE-IT Dynamic Charging Platform, which supports various charging models such as pre-pay, post-pay, and now-pay for data services.
Founded in 1998, Netasq is an information security company based in France. It has designed and markets Unified Threat Management solutions (hardware appliances based on a derivative of FreeBSD) which combine network and application firewall with embedded anti-virus, anti-spam, VPN and content filtering functionality with an integrated real-time intrusion prevention technology: the ASQ (Active Security Qualification).
BoostWorks
Series C in 2003
Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions.
Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network.
BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.
METabolic EXplorer
Series A in 2000
METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.